Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 38474373)

  • 21. Protein kinase N controls a lysosomal lipid switch to facilitate nutrient signalling via mTORC1.
    Wallroth A; Koch PA; Marat AL; Krause E; Haucke V
    Nat Cell Biol; 2019 Sep; 21(9):1093-1101. PubMed ID: 31451768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapamycin prevents cadmium-induced neuronal cell death via targeting both mTORC1 and mTORC2 pathways.
    Xu C; Liu C; Liu L; Zhang R; Zhang H; Chen S; Luo Y; Chen L; Huang S
    Neuropharmacology; 2015 Oct; 97():35-45. PubMed ID: 26002629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
    Zou Z; Chen J; Yang J; Bai X
    Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.
    Fan QW; Weiss WA
    Methods Mol Biol; 2012; 821():349-59. PubMed ID: 22125077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
    Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
    Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment.
    Heinzen D; Divé I; Lorenz NI; Luger AL; Steinbach JP; Ronellenfitsch MW
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31510109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.
    Soliman GA; Acosta-Jaquez HA; Dunlop EA; Ekim B; Maj NE; Tee AR; Fingar DC
    J Biol Chem; 2010 Mar; 285(11):7866-79. PubMed ID: 20022946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamic modeling of signal transduction by mTOR complexes in cancer.
    Dorvash M; Farahmandnia M; Mosaddeghi P; Farahmandnejad M; Saber H; Khorraminejad-Shirazi M; Azadi A; Tavassoly I
    J Theor Biol; 2019 Dec; 483():109992. PubMed ID: 31493485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
    Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
    Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanistic Target of Rapamycin Signaling Activation Antagonizes Autophagy To Facilitate Zika Virus Replication.
    Sahoo BR; Pattnaik A; Annamalai AS; Franco R; Pattnaik AK
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32878890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
    Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
    Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective interference of mTORC1/RAPTOR protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism with Akt and autophagy induction.
    Ito M; Yurube T; Kakutani K; Maeno K; Takada T; Terashima Y; Kakiuchi Y; Takeoka Y; Miyazaki S; Kuroda R; Nishida K
    Osteoarthritis Cartilage; 2017 Dec; 25(12):2134-2146. PubMed ID: 28888905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
    Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent dual inhibitors of TORC1 and TORC2 complexes (KU-0063794 and KU-0068650) demonstrate in vitro and ex vivo anti-keloid scar activity.
    Syed F; Sanganee HJ; Singh S; Bahl A; Bayat A
    J Invest Dermatol; 2013 May; 133(5):1340-50. PubMed ID: 23303455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of rictor as a novel substrate of Polo-like kinase 1.
    Shao T; Liu X
    Cell Cycle; 2015; 14(5):755-60. PubMed ID: 25714006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration.
    Razmara M; Monazzam A; Skogseid B
    Cell Commun Signal; 2018 Oct; 16(1):64. PubMed ID: 30285764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
    Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
    PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current development of the second generation of mTOR inhibitors as anticancer agents.
    Zhou HY; Huang SL
    Chin J Cancer; 2012 Jan; 31(1):8-18. PubMed ID: 22059905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.
    Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB
    Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.
    Martin EC; Rhodes LV; Elliott S; Krebs AE; Nephew KP; Flemington EK; Collins-Burow BM; Burow ME
    Mol Cancer; 2014 Oct; 13():229. PubMed ID: 25283550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.